文献速递免疫规划卫生政策与健康促进

淋球菌疫苗:公共卫生价值与首选产品特性——2019年1月WHO全球利益相关方磋商报告

Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
PubMed 文献 · Vaccine · 2020-04-28

淋球菌抗菌素耐药性威胁上升及B群脑膜炎奈瑟菌疫苗可能提供交叉保护,重新激发淋球菌疫苗研发兴趣。2019年1月WHO召集多学科国际专家组磋商,旨在奠定理解淋球菌疫苗潜在健康、经济和社会价值及可接受性与使用的基础,并制定疫苗首选产品特性(PPC)。本文描述该会议主要讨论要点与结论。

要点

  • 淋球菌抗菌素耐药性威胁上升推动疫苗研发,B群脑膜炎奈瑟菌疫苗可能提供交叉保护。
  • WHO于2019年1月召开专家组磋商,聚焦疫苗价值评估与首选产品特性(PPC)制定。
  • 疫苗终极目标为预防不良性健康与生殖健康结局(如不孕)并减轻淋球菌抗菌素耐药性影响。

核心结论

  • 与会专家强调需要疫苗控制淋球菌感染,终极目标是预防不良性健康与生殖健康结局(如不孕)并减轻淋球菌抗菌素耐药性的影响。

研究设计与样本

  • 2019年1月WHO召集多学科国际专家组磋商,为理解淋球菌疫苗潜在健康、经济和社会价值及可接受性与使用奠定基础,并制定首选产品特性(PPC)。

主要发现

  • 淋球菌抗菌素耐药性威胁上升及B群脑膜炎奈瑟菌疫苗可能提供交叉保护的证据,重新激发淋球菌疫苗研发兴趣。
  • 基于多种方法的新淋球菌疫苗候选物目前处于临床前开发阶段。
  • 与会者讨论了疫苗适应证、目标人群和潜在免疫策略等PPC重要考量,并强调指导价值评估与PPC及推进疫苗开发的关键研究和数据需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked by the increasing threat of gonococcal antimicrobial resistance (AMR) and growing optimism that gonococcal vaccines are biologically feasible. Evidence suggests serogroup B Neisseria meningitidis vaccines might provide some cross-protection against N. gonorrhoeae, and new gonococcal vaccine candidates based on several approaches are currently in preclinical development. To further stimulate investment and accelerate development of gonococcal vaccines, greater understanding is needed regarding the overall value that gonococcal vaccines might have in addressing public health and societal goals in low-, middle-, and high-income country contexts and how future gonococcal vaccines might be accepted and used, if available. In January 2019, the World Health Organization (WHO) convened a multidisciplinary international group of experts to lay the groundwork for understanding the potential health, economic, and societal value of gonococcal vaccines and their likely acceptance and use, and for developing gonococcal vaccine preferred product characteristics (PPCs). WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper describes the main discussion points and conclusions from the January 2019 meeting of experts. Participants emphasized the need for vaccines to control N. gonorrhoeae infections with the ultimate goals of preventing adverse sexual and reproductive health outcomes (e.g., infertility) and reducing the impact of gonococcal AMR. Meeting participants also discussed important PPC considerations (e.g., vaccine indications, target populations, and potential immunization strategies) and highlighted crucial research and data needs for guiding the value assessment and PPCs for gonococcal vaccines and advancing gonococcal vaccine development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gottlieb SL, Ndowa F, Hook EW, et al. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine. 2020. PMID: 32359875. doi:10.1016/j.vaccine.2020.02.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。